선택적 제품 분석
허용하는 경우 개인정보 보호를 고려한 제한적 분석을 사용해 어떤 리서치 여정이 효과적인지 파악합니다. 광고 추적기나 세션 녹화는 사용하지 않습니다. 환경설정에서 이 선택을 변경할 수 있습니다. 자세한 내용은 개인정보 처리방침.
Church & Dwight Co., Inc.'s published Reduce conclusion compares the analysis-date price with fair value and potential value. Read the full report for assumptions, evidence, and material risks.
| Market cap | $23.2B | |
|---|---|---|
| Revenue (ttm) | 6.2B | |
| Net income (ttm) | 744.8M | |
| EPS (ttm) | $3.11 | |
| Shares out | 237.2M | |
| P/E (trailing) | 33.6x | |
| P/E (forward) | 23.4x | |
| Dividend | $1.23 (1.17%) | |
| Volume | 1,114,784 | |
| Beta | 0.48 |
Recent price action with selectable time range.
| Item | P1 | P2 | P3 | P4 | P5 | Trend |
|---|---|---|---|---|---|---|
| Period | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 | Trend |
| Revenue | $5.19B | $5.38B | $5.87B | $6.11B | $6.20B | +4.6% |
| Gross profit | $2.26B | $2.25B | $2.59B | $2.79B | $2.77B | +5.2% |
| Operating income | $1.08B | $597.8M | $1.06B | $807.1M | $1.08B | -0.0% |
| Net income | $827.5M | $413.9M | $755.6M | $585.3M | $736.8M | -2.9% |
| EPS (diluted) | $3.32 | $1.68 | $3.05 | $2.37 | $3.02 | -2.3% |
| EBITDA | $1.31B | $831.9M | $1.06B | $1.09B | $1.30B | -0.1% |
| R&D | $105.2M | $110.0M | $122.4M | $139.7M | $145.6M | +8.5% |
| SG&A | $606.7M | $706.0M | $889.8M | $927.8M | $988.3M | +13.0% |
Recent company headlines from major financial publishers.
The Base scenario reflects the modal operating trajectory. Consumer Domestic anchors consolidated revenue with steady volume compounding in specialty personal care offsetting flattish volume trends in mature laundry categories. Management achieves guided gross margin expansion through continuous productivity and trade optimization, while holding brand marketing at guided levels relative to sales to defend shelf space against scale peer affordability campaigns. Cash flow conversion remains robust, supporting modest annual dividend increases and disciplined bolt-on acquisitions.
Under the Bull scenario, international consumer distribution expands rapidly across Europe and Latin America, while domestic market share gains in TheraBreath and Hero accelerate as household penetration closes the gap toward broader category averages. Manufacturing productivity programs and trade optimization deliver gross margin expansion surpassing guidance, lifting operating margins beyond historical averages and driving superior free cash flow compounding.
| Ke ↓ / g → | 2.0% | 2.3% | 2.5% | 2.8% | 3.0% |
|---|---|---|---|---|---|
| 6.7% | $88.1 | $91.2 | $94.6 | $98.5 | $103 |
| 7.2% | $81.6 | $84.0 | $86.7 | $89.7 | $93.1 |
| 7.7% | $76.2 | $78.2 | $80.3 | $82.7 | $85.3 |
| 8.2% | $71.7 | $73.3 | $75.0 | $76.9 | $79.1 |
| 8.7% | $67.8 | $69.1 | $70.6 | $72.2 | $73.9 |
Upcoming earnings date and setup when available.
매월 발행된 리서치 판이 부여한 등급입니다. 등급은 분석 시점의 가격을 공정 가치와 비교한 것이며, 판단이 맞았는지에 대한 기록이 아닙니다.
| 연도 | 1월 | 2월 | 3월 | 4월 | 5월 | 6월 | 7월 | 8월 | 9월 | 10월 | 11월 | 12월 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 |